DRL-Header DRL-Header


Find FDA Investigational New Drug (IND) Submissions for Musculoskeletal in UNITED STATES


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Antibody-Oligonucleotide Conjugates

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: RTW Investments

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing May 26, 2020


            The funds will enable Avidity to advance Company's growing proprietary portfolio of multiple programs, including Its AOC treatment of myotonic dystrophy type I, to treat serious muscle disorder.